Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Gains from Sales and Divestitures: 2022-2025

Historic Gains from Sales and Divestitures for Biodesix (BDSX) over the last 4 years, with Sep 2025 value amounting to $35,000.

  • Biodesix's Gains from Sales and Divestitures rose 1650.00% to $35,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35,000, marking a year-over-year increase of 1650.00%. This contributed to the annual value of $613,000 for FY2024, which is 13.66% down from last year.
  • Biodesix's Gains from Sales and Divestitures amounted to $35,000 in Q3 2025, which was down 94.42% from $627,000 recorded in Q2 2025.
  • Biodesix's Gains from Sales and Divestitures' 5-year high stood at $710,000 during Q4 2023, with a 5-year trough of $2,000 in Q3 2024.
  • For the 3-year period, Biodesix's Gains from Sales and Divestitures averaged around $336,727, with its median value being $387,000 (2024).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first slumped by 97.40% in 2024, then skyrocketed by 1,650.00% in 2025.
  • Quarterly analysis of 4 years shows Biodesix's Gains from Sales and Divestitures stood at $357,000 in 2022, then spiked by 98.88% to $710,000 in 2023, then dropped by 13.66% to $613,000 in 2024, then surged by 1,650.00% to $35,000 in 2025.
  • Its Gains from Sales and Divestitures stands at $35,000 for Q3 2025, versus $627,000 for Q2 2025 and $486,000 for Q1 2025.